Compare Carna Biosciences vs Paloma Pharmaceuticals
Customers evaluate the quality of Carna Biosciences's products using the following success metrics.
Overview
Carna Biosciences is 21 yrs old and is based in Japan.
Carna Biosciences is a clinical-stage biopharmaceutical company. It discovers and develops therapies to treat serious unmet medical needs, focusing on small-molecule drugs, mainly targeting protein kinases and epidermal growth factor (EGF) family molecules for their role in diseases such as cancer, inflammation, and dermatitis. It was founded in 2003 and is based in Kobe, Japan.
Paloma Pharmaceuticals is 19 yrs old and is based in United States.
Paloma Pharmaceuticals, Inc. is a drug development company focusing on pathologies with a vascular component including cancer, ocular diseases (macular degeneration and diabetic retinopathy), arthritis, fibrotic diseases (pulmonary fibrosis) endometriosis, osteoporosis and skin diseases (psoriasis and atopic dermatitis). Paloma owns the intellectual property relating to a series of , small molecule drugs created through an integrated design platform incorporating , customized and industry standard computational tools that has therapeutic potential for the treatment of the foregoing diseases.
Demo Video
Investors
Mitsubishi UFJ Capital, Mitsui & Co. Global Investment
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Carna Biosciences has not claimed their profile.
Work for Carna Biosciences? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Carna Biosciences?
Claim your profile now.
Information not available because Paloma Pharmaceuticals has not claimed their profile.
Work for Paloma Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Paloma Pharmaceuticals?
Claim your profile now.